Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL361025 | 1.00 | AKT1 (1.00) | AKT1AKT2 | |
| SCHEMBL15123446 | 0.89 | AKT1 (1.00) | AKT1AKT2 | |
| SCHEMBL15123444 | 0.89 | AKT1 (1.00) | AKT1AKT2 | |
| SCHEMBL361235 | 0.86 | AKT2 (1.00) | AKT1AKT2 | |
| SCHEMBL361234 | 0.86 | AKT2 (1.00) | AKT1AKT2 | |
| SCHEMBL359628 | 0.84 | AKT1 (1.00) | AKT1AKT2 | |
| SCHEMBL15123947 | 0.84 | AKT1 (1.00) | AKT1AKT2 | |
| SCHEMBL360545 | 0.83 | AKT1 (0.71) | AKT1AKT2 | |
| SCHEMBL360544 | 0.83 | AKT1 (0.71) | AKT1AKT2 | |
| SCHEMBL361086 | 0.83 | AKT1 (1.00) | AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593451-B1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AND -PYRIDINES | BAYER IP GMBH (DE) | 2015-08-19 | — | — | EP | claimed |
| US-8975265-B2 | Substituted imidazo[1,2-a]pyrimidines and —pyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-10 | — | — | US | claimed |
| US-20130190332-A1 | Substituted Imidazo[1,2-a]pyrimidines and -pyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | claimed |
| EP-2593451-B1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AND -PYRIDINES | BAYER IP GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| EP-2593451-B1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AND -PYRIDINES | BAYER IP GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-8975265-B2 | Substituted imidazo[1,2-a]pyrimidines and —pyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-10 | — | — | US | disclosed |
| US-8975265-B2 | Substituted imidazo[1,2-a]pyrimidines and —pyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-10 | — | — | US | disclosed |
| US-20130190332-A1 | Substituted Imidazo[1,2-a]pyrimidines and -pyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-20130190332-A1 | Substituted Imidazo[1,2-a]pyrimidines and -pyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190332-A1 | Substituted Imidazo[1,2-a]pyrimidines and -pyridines | PIK3CA, PIK3CD, PIK3CB | AKT1 26/4885AKT2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.